Abstract 3175
Background
The risk of brain metastases (BM) in advanced melanoma (MM) is 40-50%. Historical median survival of MM patients (pts) with BMs was 4-5 months. Current systemic treatments with targeted therapy and immunotherapy prolong survival up to > 2 years, while prognosis of BMs carrying pts is not fully defined and optimal treatment sequencing remain unknown. We aimed to analyze the contemporary treatment outcomes in this specific group of pts.
Methods
Clinical data, course of treatment and clinical outcomes of 376 subsequent stage IV melanoma patients with BMs treated in one reference institution in period 2000-2018 were analyzed retrospectively (39% of BMs pts diagnosed before 2014).
Results
Median age for BMS diagnosis was 61, 171 pts were BRAF+ and 118 - wild-type. Median time to BMs from melanoma diagnosis was 2.3 years (8% had BMs at diagnosis). In 1st line BRAF(-) pts were treated with anti-PD-1 in 36%, chemotherapy - 46%, while BRAF(+) pts – with BRAFi/MEKi - 68% and anti-PD-1 - 5%. For the whole group median overall survival (mOS) of BRAF(+) was 7 months, while mOS BRAF(-) - 4 m. mOS for patients treated initially with BRAFi/MEKi was 9 m, while for anti-PD1 - 15 m (but it may be related to less advanced cases preferred for immunotherapy). BMs treatment modality chosen primarily was neurosurgery in 78 (21%) pts, radiotherapy - 270 (72%) with increasing use of stereotactic radiosurgery in recent years, only systemic treatment was offered to 25 (7%) pts. OS was highly affected by the number of BMs, LDH and albumin level and GPA (Graded Prognostic Assessment) scale (all p < 0.0001). mOS for pts with 1 BM was 10 months, for 2-3 – 7.4 m and for 4+ - 3.6 months. mOS was the longest for pts treated with local therapy (SRS/neurosurgery) combined with immunotherapy. We found significant improvement in OS for BM pts treated after 2013 (p < 0.0001) especially with GPA score 3 or 4 (p < 0.05) - 24-month OS rate 9% vs 28% for pts diagnosed since 2014.
Conclusions
The outcomes of patients with BMs is highly improved when local therapy (neurosurgery +/- SRS) is combined with modern systemic therapy. The introduction of new therapies significantly improved survival of melanoma pts with BMs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
Funding
Has not received any funding.
Disclosure
I. Lugowska: Honoraria (self), Research grant / Funding (institution): Roche; Honoraria (self): BMS. H. Kosela-Paterczyk: Honoraria (self): Novartis; Honoraria (self): BMS.A.M. Czarnecka: Honoraria (self), Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BMS; Honoraria (self), Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis. P. Rutkowski: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Honoraria (self): Roche; Honoraria (self): Amgen; Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy: Blueprint Medicines; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
4900 - Molecular profiling and prognostic significance of TP53 mutations in Diffuse Large B Cell Lymphoma: identifying a high-risk subgroup
Presenter: Yuan-Kai Shi
Session: Poster Display session 3
Resources:
Abstract
3809 - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Presenter: Vikas Gaur
Session: Poster Display session 3
Resources:
Abstract
4750 - Circulating tumour cells in head and neck and non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster Display session 3
Resources:
Abstract
3704 - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Presenter: Xiaoshen Zhang
Session: Poster Display session 3
Resources:
Abstract
2235 - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience
Presenter: Reham Rashed
Session: Poster Display session 3
Resources:
Abstract
2788 - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.
Presenter: Helene Vanacker
Session: Poster Display session 3
Resources:
Abstract
4689 - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy
Presenter: Samuel Jacobs
Session: Poster Display session 3
Resources:
Abstract
1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Presenter: Hye Sook Han
Session: Poster Display session 3
Resources:
Abstract
5574 - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide
Presenter: Hsiao-Wang Chen
Session: Poster Display session 3
Resources:
Abstract
1787 - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer
Presenter: Yasushi Sato
Session: Poster Display session 3
Resources:
Abstract